NASDAQ:NGNE Neurogene (NGNE) Stock Price, News & Analysis $48.55 -1.42 (-2.84%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About Neurogene Stock (NASDAQ:NGNE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Neurogene alerts:Sign Up Key Stats Today's Range$48.15▼$51.4250-Day Range$32.82▼$54.4052-Week Range$12.49▼$55.21Volume119,113 shsAverage Volume120,149 shsMarket Capitalization$630.18 millionP/E RatioN/ADividend YieldN/APrice Target$51.00Consensus RatingBuy Company OverviewNeurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Neurogene Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks10th Percentile Overall ScoreNGNE MarketRank™: Neurogene scored higher than 10% of companies evaluated by MarketBeat, and ranked 963rd out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.6 / 5Analyst RatingBuy Consensus RatingNeurogene has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNeurogene has only been the subject of 1 research reports in the past 90 days.Read more about Neurogene's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Neurogene are expected to grow in the coming year, from ($4.47) to ($4.31) per share.Price to Book Value per Share RatioNeurogene has a P/B Ratio of 3.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Neurogene's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.48% of the float of Neurogene has been sold short.Short Interest Ratio / Days to CoverNeurogene has a short interest ratio ("days to cover") of 16.8, which indicates bearish sentiment.Change versus previous monthShort interest in Neurogene has recently increased by 6.15%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeurogene does not currently pay a dividend.Dividend GrowthNeurogene does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted18.48% of the float of Neurogene has been sold short.Short Interest Ratio / Days to CoverNeurogene has a short interest ratio ("days to cover") of 16.8, which indicates bearish sentiment.Change versus previous monthShort interest in Neurogene has recently increased by 6.15%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.64 News SentimentNeurogene has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Neurogene this week, compared to 1 article on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Neurogene insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.92% of the stock of Neurogene is held by insiders.Percentage Held by Institutions52.37% of the stock of Neurogene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neurogene's insider trading history. Receive NGNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurogene and its competitors with MarketBeat's FREE daily newsletter. Email Address NGNE Stock News HeadlinesPromising Therapeutic Potential of Neurogene’s NGN-401 in Treating Rett Syndrome Drives Buy RatingOctober 23 at 10:38 PM | markets.businessinsider.comPromising Investment Opportunity in Neurogene: Positive Developments in Rett Syndrome Treatment with NGN-401October 17, 2024 | markets.businessinsider.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)L'action Neurogene reste stable selon BMO CapitalOctober 16, 2024 | fr.investing.comLe titre NGNE atteint un sommet de 52 semaines à 53,2$, porté par une forte croissanceOctober 16, 2024 | fr.investing.comNeurogene's (NASDAQ:NGNE) Earnings Might Be Weaker Than You ThinkAugust 17, 2024 | finance.yahoo.comBuy Rating for Neurogene: Promising Rett Syndrome Program and Strong Financial OutlookAugust 15, 2024 | markets.businessinsider.comBuy Rating on Neurogene Backed by Strong 2Q24 Earnings and Promising Pipeline ProgressAugust 13, 2024 | markets.businessinsider.comSee More Headlines NGNE Stock Analysis - Frequently Asked Questions How have NGNE shares performed this year? Neurogene's stock was trading at $19.38 at the start of the year. Since then, NGNE stock has increased by 150.5% and is now trading at $48.55. View the best growth stocks for 2024 here. How were Neurogene's earnings last quarter? Neurogene Inc. (NASDAQ:NGNE) announced its earnings results on Friday, August, 9th. The company reported ($1.09) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by $0.07. The company earned $0.93 million during the quarter. Who are Neurogene's major shareholders? Neurogene's top institutional investors include SG Americas Securities LLC (0.03%). How do I buy shares of Neurogene? Shares of NGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Neurogene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neurogene investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE) and Disc Medicine (IRON). Company Calendar Last Earnings8/09/2024Today10/23/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NGNE Previous SymbolNASDAQ:NGNE CUSIPN/A CIK1404644 Webwww.neurogene.com Phone(877) 237-5020Fax778-331-4486Employees90Year FoundedN/APrice Target and Rating Average Stock Price Target$51.00 High Stock Price Target$65.00 Low Stock Price Target$31.00 Potential Upside/Downside+5.0%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,320,000.00 Net MarginsN/A Pretax Margin-5,146.70% Return on Equity-32.44% Return on Assets-27.70% Debt Debt-to-Equity RatioN/A Current Ratio12.17 Quick Ratio12.17 Sales & Book Value Annual Sales$925,000.00 Price / Sales681.27 Cash FlowN/A Price / Cash FlowN/A Book Value$14.51 per share Price / Book3.35Miscellaneous Outstanding Shares12,980,000Free Float11,705,000Market Cap$630.18 million OptionableOptionable Beta1.50 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report This page (NASDAQ:NGNE) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.